Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats.
Dyslipidemia
Lipid peroxidation
Nonalcoholic fatty liver disease, Silymarin
Reduced glutathione
Total antioxidant status
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
30 Mar 2021
30 Mar 2021
Historique:
received:
17
02
2020
accepted:
15
03
2021
entrez:
31
3
2021
pubmed:
1
4
2021
medline:
6
11
2021
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the Western world, and it's likely to parallel the increasing prevalence of type 2 diabetes, obesity, and other components of metabolic syndrome. However, optimal treatment for NAFLD has not been established yet. Therefore, this study investigated the hepatoprotective effect of silymarin on fructose-induced nonalcoholic fatty liver disease in rats. Thirty male Wistar rats were randomly divided into five groups; normal control group that consumed tap water, silymarin control group that consumed tap water and silymarin (400 mg/kg/day), fructose control group that consumed 20% fructose solution, treatment group that consumed 20% fructose solution and silymarin (200 mg/kg/day), and another treatment group that consumed 20% fructose solution and silymarin (400 mg/kg/day). Hepatic triglyceride, serum lipid profile, lipid peroxidation, antioxidant level, morphological features, and histopathological changes were investigated. The data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey multiple comparison test. Statistical significance was determined at p < 0.05. This study showed that the fructose control group had a significantly high value in the stage of steatosis grade, hepatic triglyceride, serum triglyceride, total cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, and hepatic malondialdehyde concentration as compared to the normal control. However, significantly low values of reduced glutathione and plasma total antioxidant capacity were found. The altered parameters due to fructose drastic effect were ameliorated by silymarin treatment. The fructose control group developed dyslipidemia, oxidative stress, and mild steatosis that are the characteristics features of NAFLD. However, silymarin-treated groups showed amelioration in oxidative stress, dyslipidemia, and steatosis.
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the Western world, and it's likely to parallel the increasing prevalence of type 2 diabetes, obesity, and other components of metabolic syndrome. However, optimal treatment for NAFLD has not been established yet. Therefore, this study investigated the hepatoprotective effect of silymarin on fructose-induced nonalcoholic fatty liver disease in rats.
METHODS
METHODS
Thirty male Wistar rats were randomly divided into five groups; normal control group that consumed tap water, silymarin control group that consumed tap water and silymarin (400 mg/kg/day), fructose control group that consumed 20% fructose solution, treatment group that consumed 20% fructose solution and silymarin (200 mg/kg/day), and another treatment group that consumed 20% fructose solution and silymarin (400 mg/kg/day). Hepatic triglyceride, serum lipid profile, lipid peroxidation, antioxidant level, morphological features, and histopathological changes were investigated. The data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey multiple comparison test. Statistical significance was determined at p < 0.05.
RESULTS
RESULTS
This study showed that the fructose control group had a significantly high value in the stage of steatosis grade, hepatic triglyceride, serum triglyceride, total cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, and hepatic malondialdehyde concentration as compared to the normal control. However, significantly low values of reduced glutathione and plasma total antioxidant capacity were found. The altered parameters due to fructose drastic effect were ameliorated by silymarin treatment.
CONCLUSIONS
CONCLUSIONS
The fructose control group developed dyslipidemia, oxidative stress, and mild steatosis that are the characteristics features of NAFLD. However, silymarin-treated groups showed amelioration in oxidative stress, dyslipidemia, and steatosis.
Identifiants
pubmed: 33785007
doi: 10.1186/s12906-021-03275-5
pii: 10.1186/s12906-021-03275-5
pmc: PMC8011178
doi:
Substances chimiques
Antioxidants
0
Lipids
0
Silymarin
0
Triglycerides
0
Fructose
30237-26-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Commentaires et corrections
Type : ErratumIn
Références
Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol. 2009;8(S1):51–9.
doi: 10.1016/S1665-2681(19)31827-7
Pettinelli P, Obregón A, Videla L. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp. 2011;26(3):441–50. https://doi.org/10.1590/S0212-16112011000300003 .
doi: 10.1590/S0212-16112011000300003
pubmed: 21892559
Longato L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6(1):1–5.
doi: 10.1186/1755-1536-6-14
Qiu L-X, Chen T. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease. World J Gastroenterol: WJG. 2015;21(4):1099–107. https://doi.org/10.3748/wjg.v21.i4.1099 .
doi: 10.3748/wjg.v21.i4.1099
pubmed: 25632182
pmcid: 4306153
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431 .
doi: 10.1002/hep.28431
pubmed: 26707365
Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci. 2011;7(1):8–20. https://doi.org/10.5114/aoms.2011.20598 .
doi: 10.5114/aoms.2011.20598
pubmed: 22291727
pmcid: 3258689
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46. https://doi.org/10.1002/hep.24001 .
doi: 10.1002/hep.24001
pubmed: 21038418
pmcid: 21038418
Bray GA: Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people. In: Oxford University Press; 2013.
Voinovich D, Perissutti B, Grassi M, Passerini N, Bigotto A. Solid state mechanochemical activation of Silybum marianum dry extract with betacyclodextrins: characterization and bioavailability of the coground systems. J Pharm Sci. 2009;98(11):4119–29. https://doi.org/10.1002/jps.21704 .
doi: 10.1002/jps.21704
pubmed: 19226635
Pradhan S, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491–504.
pubmed: 17213517
Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–32. https://doi.org/10.1002/ptr.3207 .
doi: 10.1002/ptr.3207
pubmed: 20564545
Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H, et al. Hepat Mon. 2012;12:8.
doi: 10.5812/hepatmon.6099
Aller R, Izaola O, Gómez S, Tafur C, Gonzalez G, Berroa E, Mora N, Gonzalez J, De Luis D. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19(16):3118–24.
pubmed: 26367736
Hajiani E, Jalal Hashemi S. Comparison of therapeutic effects of silymarin and vitamin e in nonalcoholic fatty liver disease: results of an open-labele, prospective, randomized study. Jundishapur J Nat Pharmaceut Products. 2009;4(1):8–14.
Solhi H, Ghahremani R, Kazemifar AM, Yazdi ZH. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med. 2014;5(1):9–12.
pubmed: 24490006
pmcid: 3894463
Mamikutty N, Thent ZC, Haji Suhaimi F. Fructose-drinking water induced nonalcoholic fatty liver disease and ultrastructural alteration of hepatocyte mitochondria in male Wistar rat. Biomed Res Int. 2015;2015:1–7. https://doi.org/10.1155/2015/895961 .
doi: 10.1155/2015/895961
OECD O. Guidance document on acute oral toxicity testing. Paris: OECD; 2000.
Radko L, Cybulski W. Application of silymarin in human and animal medicine. J Pre-Clin Clin Res. 2007:1.
Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1(2):87–93. https://doi.org/10.4103/0976-500X.72350 .
doi: 10.4103/0976-500X.72350
pubmed: 21350616
pmcid: 3043327
Ruehl-Fehlert C, Kittel B, Morawietz G, Deslex P, Keenan C, Mahrt CR, Nolte T, Robinson M, Stuart BP, Deschl U. Revised guides for organ sampling and trimming in rats and mice–part 1: a joint publication of the RITA and NACAD groups. Exp Toxicol Pathol. 2003;55(2–3):91–106. https://doi.org/10.1078/0940-2993-00311 .
doi: 10.1078/0940-2993-00311
pubmed: 14620530
Folch J, Lees M, Stanley GS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497–509. https://doi.org/10.1016/S0021-9258(18)64849-5 .
doi: 10.1016/S0021-9258(18)64849-5
Danno H, Jincho Y, Budiyanto S, Furukawa Y, Kimura S. A simple enzymatic quantitative analysis of triglycerides in tissues. J Nutr Sci Vitaminol. 1992;38(5):517–21. https://doi.org/10.3177/jnsv.38.517 .
doi: 10.3177/jnsv.38.517
pubmed: 1294711
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–8. https://doi.org/10.1016/0003-2697(79)90738-3 .
doi: 10.1016/0003-2697(79)90738-3
Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277–85. https://doi.org/10.1016/j.clinbiochem.2003.11.015 .
doi: 10.1016/j.clinbiochem.2003.11.015
pubmed: 15003729
Gupta R, Sharma M, Lakshmy R, Prabhakaran D, Reddy KS: Improved method of total antioxidant assay. 2009.
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7. https://doi.org/10.1016/0003-9861(59)90090-6 .
doi: 10.1016/0003-9861(59)90090-6
pubmed: 13650640
Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968;25(1):192–205. https://doi.org/10.1016/0003-2697(68)90092-4 .
doi: 10.1016/0003-2697(68)90092-4
Quaresma AB, d'Acampora AJ, Tramonte R, DCd F, Joly FS. Histological study of the liver and biochemistry of the blood of Wistar rats following ligature of right hepatic duct. Acta Cirurgica Brasileira. 2007;22(1):68–78. https://doi.org/10.1590/S0102-86502007000100013 .
doi: 10.1590/S0102-86502007000100013
pubmed: 17293954
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. https://doi.org/10.1002/hep.20701 .
doi: 10.1002/hep.20701
pubmed: 15915461
Rodrigues AA, Andrade RS, Vasconcelos DF. Relationship between experimental diet in rats and nonalcoholic hepatic disease: review of literature. Int J Hepatol. 2018:1–8. https://doi.org/10.1155/2018/9023027 .
Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease—a starter’s guide. Nutrients. 2017;9(10):1072. https://doi.org/10.3390/nu9101072 .
doi: 10.3390/nu9101072
pmcid: 5691689
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. https://doi.org/10.1002/hep.25762 .
doi: 10.1002/hep.25762
pubmed: 22488764
Kim M, Yang S-G, Kim JM, Lee J-W, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: Αnalysis of isolated hepatic stellate cells. Int J Mol Med. 2012;30(3):473–9. https://doi.org/10.3892/ijmm.2012.1029 .
doi: 10.3892/ijmm.2012.1029
pubmed: 22710359
pmcid: 3573753
Prakash P, Singh V, Jain M, Rana M, Khanna V, Barthwal MK, Dikshit M. Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. Eur J Pharmacol. 2014;727:15–28. https://doi.org/10.1016/j.ejphar.2014.01.038 .
doi: 10.1016/j.ejphar.2014.01.038
pubmed: 24486395
Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Petrella A, Tamborra R, Romano AD, Rollo T, Vendemiale G, Altomare E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2010;332(3):922–32. https://doi.org/10.1124/jpet.109.161612 .
doi: 10.1124/jpet.109.161612
pubmed: 20008062
Tsai J, Liu J-Y, Wu T, Ho P, Huang C-Y, Shyu J, Hsieh Y, Tsai C, Liu Y. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. J Viral Hepat. 2008;15(7):508–14. https://doi.org/10.1111/j.1365-2893.2008.00971.x .
doi: 10.1111/j.1365-2893.2008.00971.x
pubmed: 18397225
Wu J-P, Tsai C-C, Yeh Y-L, Lin Y-M, Lin C-C, Day CH, Shen C-Y, Padma VV, Pan L-F, Huang C-Y. Silymarin accelerates liver regeneration after partial hepatectomy. Evid Based Complement Alternat Med. 2015;2015:1–14. https://doi.org/10.1155/2015/603529 .
doi: 10.1155/2015/603529
Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 2013;46(3):270–7. https://doi.org/10.1590/1414-431X20122551 .
doi: 10.1590/1414-431X20122551
pubmed: 23532271
pmcid: 3854368
Abdulla MH, Sattar MA, Abdullah NA, Khan MAH, Swarup KRA, Johns EJ. The contribution of α 1B-adrenoceptor subtype in the renal vasculature of fructose-fed Sprague–Dawley rats. Eur J Nutr. 2011;50(4):251–60. https://doi.org/10.1007/s00394-010-0133-8 .
doi: 10.1007/s00394-010-0133-8
pubmed: 20882287
Wang J, Gao H, Ke D, Zuo G, Yang Y, Yamahara J, Li Y. Improvement of liquid fructose-induced adipose tissue insulin resistance by ginger treatment in rats is associated with suppression of adipose macrophage-related proinflammatory cytokines. Evid Based Complement Alternat Med. 2013;2013:1–12. https://doi.org/10.1155/2013/590376 .
Cardinali DP, Bernasconi PAS, Reynoso R, Toso CFR, Scacchi P. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats. Int J Mol Sci. 2013;14(2):2502–14. https://doi.org/10.3390/ijms14022502 .
doi: 10.3390/ijms14022502
pubmed: 23354480
pmcid: 3587998
Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res. 2016;8(2):1073–81.
pubmed: 27158393
pmcid: 4846950
Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol. 2008;48(6):983–92. https://doi.org/10.1016/j.jhep.2008.01.035 .
doi: 10.1016/j.jhep.2008.01.035
pubmed: 18395289
Jürgens H, Haass W, Castaneda TR, Schürmann A, Koebnick C, Dombrowski F, Otto B, Nawrocki AR, Scherer PE, Spranger J. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res. 2005;13(7):1146–56. https://doi.org/10.1038/oby.2005.136 .
doi: 10.1038/oby.2005.136
pubmed: 16076983
Guo Y, Wang S, Wang Y, Zhu T. Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol. 2016;54(12):2995–3000. https://doi.org/10.1080/13880209.2016.1199042 .
doi: 10.1080/13880209.2016.1199042
pubmed: 27387273
Sayin FK, Buyukbas S, Basarali MK, Alp H, Toy H, Ugurcu V. Effects of Silybum marianum extract on high-fat diet induced metabolic disorders in rats. Polish J Food Nutr Sci. 2016;66(1):43–50. https://doi.org/10.1515/pjfns-2015-0014 .
doi: 10.1515/pjfns-2015-0014
Poudyal H, Panchal SK, Ward LC, Waanders J, Brown L. Chronic high-carbohydrate, high-fat feeding in rats induces reversible metabolic, cardiovascular, and liver changes. Am J Physiol-Endocrinol Metab. 2012;302(12):E1472–82. https://doi.org/10.1152/ajpendo.00102.2012 .
doi: 10.1152/ajpendo.00102.2012
pubmed: 22436699
Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med. 2011;2011:1–10. https://doi.org/10.1093/ecam/nep164 .
doi: 10.1093/ecam/nep164
Liu S-H, Cai F-Y, Chiang M-T. Long-term feeding of chitosan ameliorates glucose and lipid metabolism in a high-fructose-diet-impaired rat model of glucose tolerance. Marine Drugs. 2015;13(12):7302–13. https://doi.org/10.3390/md13127067 .
doi: 10.3390/md13127067
pubmed: 26690452
pmcid: 4699240
Senaphan K, Kukongviriyapan U, Sangartit W, Pakdeechote P, Pannangpetch P, Prachaney P, Greenwald SE, Kukongviriyapan V. Ferulic acid alleviates changes in a rat model of metabolic syndrome induced by high-carbohydrate, high-fat diet. Nutrients. 2015;7(8):6446–64. https://doi.org/10.3390/nu7085283 .
doi: 10.3390/nu7085283
pubmed: 26247970
pmcid: 4555122
Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi PJ, Tiribelli C. Effects of oral administration of silymarin in a juvenile murine model of non-alcoholic steatohepatitis. Nutrients. 2017;9(9):1006. https://doi.org/10.3390/nu9091006 .
doi: 10.3390/nu9091006
pmcid: 5622766
Sun R, Xu D, Wei Q, Zhang B, Aa J, Wang G, Xie Y. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020;123:109721. https://doi.org/10.1016/j.biopha.2019.109721 .
doi: 10.1016/j.biopha.2019.109721
pubmed: 31865143
Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012;55(4):1103–11. https://doi.org/10.1002/hep.24737 .
doi: 10.1002/hep.24737
pubmed: 21994008
Aragno M, Tomasinelli CE, Vercellinatto I, Catalano MG, Collino M, Fantozzi R, Danni O, Boccuzzi G. SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med. 2009;47(7):1067–74. https://doi.org/10.1016/j.freeradbiomed.2009.07.016 .
doi: 10.1016/j.freeradbiomed.2009.07.016
pubmed: 19616615
Panchal SK, Wong W-Y, Kauter K, Ward LC, Brown L. Caffeine attenuates metabolic syndrome in diet-induced obese rats. Nutrition. 2012;28(10):1055–62. https://doi.org/10.1016/j.nut.2012.02.013 .
doi: 10.1016/j.nut.2012.02.013
pubmed: 22721876
Sabiu S, Sunmonu TO, Ajani EO, Ajiboye TO. Combined administration of silymarin and vitamin C stalls acetaminophen-mediated hepatic oxidative insults in Wistar rats. Rev Bras. 2015;25(1):29–34. https://doi.org/10.1016/j.bjp.2014.11.012 .
doi: 10.1016/j.bjp.2014.11.012
Armutcu F, Coskun Ö, Gürel A, Kanter M, Can M, Ucar F, Unalacak M. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem. 2005;38(6):540–7. https://doi.org/10.1016/j.clinbiochem.2005.01.013 .
doi: 10.1016/j.clinbiochem.2005.01.013
pubmed: 15885234
Du D, Shi Y-H, Le G-W. Oxidative stress induced by high-glucose diet in liver of C57BL/6J mice and its underlying mechanism. Mol Biol Rep. 2010;37(8):3833–9. https://doi.org/10.1007/s11033-010-0039-9 .
doi: 10.1007/s11033-010-0039-9
pubmed: 20217240
Takeuchi M, Iwaki M, Takino J-I, Shirai H, Kawakami M, Bucala R, Yamagishi S-I. Immunological detection of fructose-derived advanced glycation end-products. Lab Investig. 2010;90(7):1117–27. https://doi.org/10.1038/labinvest.2010.62 .
doi: 10.1038/labinvest.2010.62
pubmed: 20212455
Grasselli E, Baldini F, Vecchione G, Oliveira PJ, Sardão VA, Voci A, Portincasa P, Vergani L. Excess fructose and fatty acids trigger a model of non-alcoholic fatty liver disease progression in vitro: protective effect of the flavonoid silybin. Int J Mol Med. 2019;44(2):705–12. https://doi.org/10.3892/ijmm.2019.4234 .
doi: 10.3892/ijmm.2019.4234
pubmed: 31173180
Kheiripour N, Karimi J, Khodadadi I, Tavilani H, Goodarzi MT, Hashemnia M. Hepatoprotective effects of silymarin on liver injury via irisin upregulation and oxidative stress reduction in rats with type 2 diabetes. Iran J Med Sci. 2019;44(2):108–17.
pubmed: 30936597
Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol. 2010;48(3):803–6. https://doi.org/10.1016/j.fct.2009.12.011 .
doi: 10.1016/j.fct.2009.12.011
pubmed: 20034535
Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res. 2011;44(7):652–9. https://doi.org/10.1590/s0100-879x2011007500083 .
doi: 10.1590/s0100-879x2011007500083
pubmed: 21755261
Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, Leoni S, Bottazzo GF, Masotti A, Nobili V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Investig. 2011;91(2):283–93. https://doi.org/10.1038/labinvest.2010.166 .
doi: 10.1038/labinvest.2010.166
pubmed: 20956972